{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:07:58Z","timestamp":1791176878314,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.vaccine.2006.05.061","type":"journal-article","created":{"date-parts":[[2006,6,11]],"date-time":"2006-06-11T12:00:42Z","timestamp":1150027242000},"page":"S171-S177","source":"Crossref","is-referenced-by-count":146,"special_numbering":"S3","title":["Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination"],"prefix":"10.1016","volume":"24","author":[{"given":"Eduardo L.","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Cuzick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Hildesheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"de Sanjos\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9447","key":"10.1016\/j.vaccine.2006.05.061_bib1","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2006.05.061_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.05.061_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"9518","key":"10.1016\/j.vaccine.2006.05.061_bib4","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2006.05.061_bib5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.290.6.781","article-title":"Potential health and economic impact of adding a human papillomavirus vaccine to screening programs","volume":"290","author":"Kulasingam","year":"2003","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.vaccine.2006.05.061_bib6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.vaccine.2006.05.061_bib7","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2006.05.061_bib8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.AOG.0000115510.81613.f0","article-title":"Cervical screening in the national breast and cervical cancer early detection program, 1995\u20132001","volume":"103","author":"Benard","year":"2004","journal-title":"Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.vaccine.2006.05.061_bib9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-132-10-200005160-00009","article-title":"Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review","volume":"132","author":"Nanda","year":"2000","journal-title":"Ann Intern Med"},{"issue":"31","key":"10.1016\/j.vaccine.2006.05.061_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/oxfordjournals.jncimonographs.a003488","article-title":"Chapter 13: Primary screening of cervical cancer with human papillomavirus tests","author":"Franco","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"5","key":"10.1016\/j.vaccine.2006.05.061_bib11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-04-0812","article-title":"Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer","volume":"14","author":"Clifford","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"14","key":"10.1016\/j.vaccine.2006.05.061_bib12","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/jnci\/dji186","article-title":"Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities","volume":"97","author":"Castle","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.vaccine.2006.05.061_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.virol.2005.04.002","article-title":"The carcinogenicity of human papillomavirus types reflects viral evolution","volume":"337","author":"Schiffman","year":"2005","journal-title":"Virology"},{"issue":"suppl 6","key":"10.1016\/j.vaccine.2006.05.061_bib14","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jadohealth.2005.09.010","article-title":"Improving adolescent health: focus on HPV vaccine acceptance","volume":"37","author":"Zimet","year":"2005","journal-title":"J Adolesc Health"},{"issue":"suppl 1","key":"10.1016\/j.vaccine.2006.05.061_bib15","doi-asserted-by":"crossref","first-page":"s23","DOI":"10.1097\/01.gco.0000216317.10690.8f","article-title":"Understanding and overcoming barriers to human papillomavirus vaccine acceptance","volume":"18","author":"Zimet","year":"2006","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.vaccine.2006.05.061_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jpag.2005.09.004","article-title":"Attitudes about human papillomavirus vaccine among family physicians","volume":"18","author":"Riedesel","year":"2005","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.vaccine.2006.05.061_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and North American studies on HPV testing in primary cervical cancer screening","author":"Cuzick","year":"2006","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.vaccine.2006.05.061_bib18","first-page":"945","article-title":"Human papillomavirus testing for primary screening of cervical cancer precursors","volume":"9","author":"Ratnam","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.vaccine.2006.05.061_bib19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ijc.21897","article-title":"Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST)","volume":"119","author":"Mayrand","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2006.05.061_bib20","unstructured":"IARC Working Group. Cervix cancer screening. IARC handbooks of cancer prevention, Lyon: International Agency for Research on Cancer, World Health Organization, IARC Press; 2005."},{"issue":"9399","key":"10.1016\/j.vaccine.2006.05.061_bib21","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0140-6736(03)14955-0","article-title":"Management of women who test positive for high-risk types of human papillomavirus: the HART study","volume":"362","author":"Cuzick","year":"2003","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06006177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06006177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T23:53:37Z","timestamp":1547596417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06006177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":21,"alternative-id":["S0264410X06006177"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.05.061","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}